Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Fitxers

700167.pdf (1.67 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2019-10-31

Llicència de publicació

cc-by-nc-nd (c) Torres et. al. , 2019
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/171086

Economic analysis of ceftaroline fosamil for treating community-acquired pneumonia in Spain

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1080/13696998.2019.1688819

Resum

Background: Adults admitted to hospital with community-acquired pneumonia (CAP) impose significant burden upon limited hospital resources. To achieve early response and possibly early discharge, thus reducing hospital expenditure, the choice of initial antibiotic therapy is pivotal.Methods: A cost-consequences model was developed to evaluate ceftaroline fosamil (CFT) as an alternative to other antibiotic therapies (ceftriaxone, co-amoxiclav, moxifloxacin, levofloxacin) for the empiric treatment of hospitalized adults with moderate/severe CAP (PORT score III-IV) from the perspective of the Spanish National Health System (NHS).Findings: Compared with ceftriaxone, the model predicted an increase in the number of CFT-treated patients discharged early (PDE) (30.6% vs. 26.1%) while decreasing initial antibiotic failures (3.8% vs. 7.6%). For patients with pneumococcal pneumonia, CFT was cost-saving vs. ceftriaxone (by 1.2%) and significantly increased PDE (32.1% vs. 24.6%). CFT resulted in cost-saving vs. levofloxacin, due lower initial antibiotic therapy costs and increased PDE (30.6% vs. 14.9%). Moxifloxacin and co-amoxiclav early response rate of 53.63% and 54.24% resulted in cost neutrality vs. CFT, with direct comparison hampered by the significantly different early response criteria utilized in the literature.Conclusions: Despite a higher unit cost, CFT is a reasonable alternative to other agents for adults hospitalized with moderate/severe CAP, given the projected higher PDE achieved with similar or lower total costs.

Matèries

Pneumònia adquirida a la comunitat, Antibiòtics

Matèries (anglès)

Community-acquired pneumonia, Antibiotics

Citació

Col·leccions

Articles publicats en revistes (Medicina)

Citació

TORRES MARTÍ, Antoni, et al. Economic analysis of ceftaroline fosamil for treating community-acquired pneumonia in Spain. Journal of Media Economics. 2019. Vol. 23, num. 2, pags. 148-155. ISSN 0899-7764. [consulted: 19 of August of 2026]. Available at: https://hdl.handle.net/2445/171086

Exportar metadades

JSON - METS

Compartir registre